Our top pick for
AMAG Pharmaceuticals Inc is a biotechnology business based in the US. AMAG Pharmaceuticals shares (AMAG) are listed on the NASDAQ and all prices are listed in US Dollars. AMAG Pharmaceuticals employs 440 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$13.61 - $13.76|
|50-day moving average||$13.72|
|200-day moving average||$10.32|
|Wall St. target price||$11.96|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.83|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing AMAG Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AMAG Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AMAG Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AMAG Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$300.1 million|
|Gross profit TTM||$219.4 million|
|Return on assets TTM||-3.06%|
|Return on equity TTM||0%|
|Market capitalisation||$477.5 million|
TTM: trailing 12 months
There are currently 6.3 million AMAG Pharmaceuticals shares held short by investors – that's known as AMAG Pharmaceuticals's "short interest". This figure is 13% down from 7.2 million last month.
There are a few different ways that this level of interest in shorting AMAG Pharmaceuticals shares can be evaluated.
AMAG Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AMAG Pharmaceuticals shares currently shorted divided by the average quantity of AMAG Pharmaceuticals shares traded daily (recently around 3.4 million). AMAG Pharmaceuticals's SIR currently stands at 1.83. In other words for every 100,000 AMAG Pharmaceuticals shares traded daily on the market, roughly 1830 shares are currently held short.
However AMAG Pharmaceuticals's short interest can also be evaluated against the total number of AMAG Pharmaceuticals shares, or, against the total number of tradable AMAG Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AMAG Pharmaceuticals's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 AMAG Pharmaceuticals shares in existence, roughly 180 shares are currently held short) or 0.3803% of the tradable shares (for every 100,000 tradable AMAG Pharmaceuticals shares, roughly 380 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AMAG Pharmaceuticals.
Find out more about how you can short AMAG Pharmaceuticals stock.
We're not expecting AMAG Pharmaceuticals to pay a dividend over the next 12 months.
AMAG Pharmaceuticals's shares were split on a 3:2 basis on 25 September 1991. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your AMAG Pharmaceuticals shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for AMAG Pharmaceuticals shares which in turn could have impacted AMAG Pharmaceuticals's share price.
Over the last 12 months, AMAG Pharmaceuticals's shares have ranged in value from as little as $13.61 up to $13.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AMAG Pharmaceuticals's is 0.8675. This would suggest that AMAG Pharmaceuticals's shares are less volatile than average (for this exchange).
AMAG Pharmaceuticals, Inc. , a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc. , Palatin Technologies, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.